Targeting CD36 as Biomarker for Metastasis Prognostic: How Far from Translation into Clinical Practice?

Table 1

Involvement of CD36 in various types of cancer—data from human sample studies.

Type of cancer	Location within the tumour	Contribution of CD36	Refs
Breast cancer	Stroma tissue; Decreased endothelial expression; Tumour cells	Angiogenesis	[90]; [87]
Prostate cancer	Tumour cells	Activation of MAPK signalling, pro-invasion	[91]
Ovarian cancer	Tumour cells harvested from patient ascites	Pro-metastatic	[92]
Colon cancer	Not specified	Decreased expression in metastatic cancer	[96]
Oral squamous cell carcinoma	Tumour cells	Favours lymph node and lung metastasis	[86]
Acute myeloid leukaemia	Tumour cells	Part of immunophenotyping panel used for patient stratification	[95]
Glioblastoma	Tumour cells	Maintenance of stemness features, tumour initiation	[85]
Hepatocellular carcinoma	Not mentioned	Increased CD36 is associated with epithelial-to-mesenchymal transduction	[101]